Dr. Hu on the Next Steps for Biopsies in Prostate Cancer

Jim Hu, MD, MPH
Published: Tuesday, Aug 29, 2017



Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at Weill Cornell Medicine/NewYork-Presbyterian Hospital and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses the next steps of biopsies for patients with prostate cancer.

It has become an individual choice of whether a patient should receive a prostate biopsy, explains Hu. This aligns with what other professional organizations are saying. However, it is known that if you compare the use of prostate-specific antigen screening versus monography, it compares quite favorably in terms of the number of men needed to screen to prevent death.
 


Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at Weill Cornell Medicine/NewYork-Presbyterian Hospital and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses the next steps of biopsies for patients with prostate cancer.

It has become an individual choice of whether a patient should receive a prostate biopsy, explains Hu. This aligns with what other professional organizations are saying. However, it is known that if you compare the use of prostate-specific antigen screening versus monography, it compares quite favorably in terms of the number of men needed to screen to prevent death.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x